Guttify plans Rs 20 Cr fundraise as gut health moves mainstream in India
Delhi-based startup Guttify is planning to raise Rs 20 crore in its next funding round to accelerate its ambition of building one of India’s leading consumer gut health platforms. The company’s most recent funding valued Guttify at approximately Rs 54 crore. The proposed fundraise comes at a time when gut health is rapidly moving from a niche wellness conversation to a mainstream consumer health category, driven by rising awareness around digestion, metabolic health, the microbiome and preventive wellness. Guttify is currently witnessing strong momentum, reporting 67% quarter-on-quarter growth, approximately 20% monthly growth in its user base, and a 40% repeat-user rate. Guttify is now preparing to raise approximately Rs 20 crore to accelerate product innovation, strengthen its technology and diagnostic capabilities, invest in consumer education and expand distribution across Tier 1 and Tier 2 India. The company also plans to significantly expand its portfolio across high-frequency digestive and metabolic wellness needs, including constipation, bloating, digestion, liver health and everyday gut wellness. The upcoming raise follows an approximate Rs 4 crore follow-on funding round in February 2026 and an approximately $360,000 extended seed round in May 2025. Guttify has raised more than Rs 10 crore cumulatively to date, with participation from the family office associated with Unichem Laboratories, existing investors and prominent Indian and international HNIs, including Amandeep Singh Sodhi, co-founder of HOAGS Technologies.
C-CAMP onboards two Dutch Medtech startups focusing on neurological disorders and cardiac health
Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP) has onboarded two Medtech startups from the Netherlands, positioning itself as a globally reckoning bio innovation destination. The startups are in the domains of neurological disorders and cardiac health. The move is catalysed by the Embassy of the Netherlands as a part of its commitment towards bilateral innovation bridge between the Netherlands and India that aims to promote exchange of innovators from mutual ecosystems. The agreements with the two startups were announced at C-CAMP premises in the presence of Dr Taslimarif Saiyed, C-CAMP Director-CEO and Anne Cremers, Acting Consul General of the Kingdom of the Netherlands in South India. Aikon Health, represented by founder Thiru Kanagasabapathi, has developed a modular, skin‑patch wearable for heart failure and an accompanying digital platform to capture longitudinal vital-sign and hemodynamic data that is interoperable with hospital/RPM systems. The technology can monitor clinically validated digital biomarkers and send out predictive alerts to support medication titration and reduce hospital readmissions. On the other hand, Alpha Brain Technologies, represented by Co-CEO & Tech lead, Mehrdad Seirafi, has developed a non-invasive, easy-to-wear medical device that predicts seizures before they happen, alerting the patient and caregiver ahead of time.
Ayati Devices raises Rs 15 Cr to scale AI-driven diabetic foot diagnostics platform
Ayati Devices, a Bengaluru-based medical technology and device manufacturing startup developing precision diagnostic solutions for diabetic foot complications and peripheral vascular disease, has raised Rs 15 Crore in a Pre-Series A funding round led by Inflexor Ventures. This marks the company's first institutional investment and will accelerate the commercialisation of its next-generation diagnostic technologies, expand its domestic and international presence, strengthen manufacturing capabilities, and deepen investments in research, regulatory approvals, artificial intelligence, and global talent. Ayati Devices has been incubated at IITB-SINE as part of the institute’s translational research programme. Ayati's technologies already hold regulatory clearances across major global markets, including CDSCO (India), the US FDA, CE Mark (Europe), and approvals in Sri Lanka, Malaysia, and the UAE. The company has deployed over 10,000 devices across 30+ countries, backed by a growing international distributor network and clinical deployments at leading institutions such as Medicover Hospital and Aster Hospital. The capital will fund Angiocam's commercialisation, expand go-to-market operations at home and abroad, strengthen manufacturing and supply chain capacity, accelerate R&D in AI-enabled diagnostics, secure further regulatory approvals, grow the IP portfolio, and build out engineering, clinical, regulatory, and global business development teams. Looking ahead, Ayati will deepen its presence across Europe, the US, the Middle East, Southeast Asia, Australia, and Latin America through its distribution network, while evaluating direct commercial operations in key markets as demand scales. It will also expand its pay-per-test screening model across hospitals, primary care clinics, and community programmes, making preventive diagnostics far more accessible.
BIRAC Startup Investor Connect to support biotechnology opportunities
Union Minister of State (Independent Charge) for Science and Technology Dr Jitendra Singh recently held a meeting with senior officials of Biotechnology Industry Research Assistance Council (BIRAC) in New Delhi, where a series of measures to expand investment, industry participation and market opportunities for India's biotechnology ecosystem were discussed. BIRAC proposes BIRAC Startup Investor Connect, a dedicated platform to bring together investor ready biotech startups and investors. The platform aims to raise awareness of biotechnology opportunities, facilitate strategic partnerships, strengthen investment networks, and accelerate the commercialisation of innovative technologies. Strengthening the reach and visibility of BIRAC was another important area of focus. BIRAC has proposed branding initiatives at Jammu and Vadodara airports to showcase the achievements of DBT-BIRAC and create awareness among corporates, investors and global partners about opportunities to collaborate with India's biotechnology ecosystem. Jammu is emerging as a major hub for biotechnology, healthcare, and agricultural innovation, while Vadodara has an established base of pharma-biotech manufacturing. The meeting also focused on leveraging the growing Life Sciences Global Capability Centre (GCC) ecosystem to increase industry participation in India's biotechnology sector. India currently has over 1,700 GCCs employing around 1.9 million professionals, while the Life Sciences and Healthcare GCC has emerged as important centres of R&D in areas including biopharmaceuticals, medical devices, and digital health. BIRAC will help in better integrating the current and potential GCC with the domestic biotechnology ecosystem by assessing their requirements in infrastructure, pilot-scale manufacturing, and R&D and linking them to India's BioE3 bio-foundries, bio-incubators and startups. BIRAC has set up a dedicated BIRAC-RDIF division to ensure smooth implementation of the Fund. A total of 198 applications have been received and are being evaluated as per the guidelines of the scheme. The first 50 applications have been screened and evaluated, with eight eligible Technology Entities selected so far on the recommendations of the Investment Committee consisting of external experts. These entities are currently undergoing a detailed vetting process before entering into debt or equity agreements.
proRITHM accelerates expansion across Southern India, eyes nationwide presence by early 2027
DeepFacts, a HealthTech startup behind proRITHM (an AI- and IoT-enabled Smart Remote Patient Monitoring platform), has announced its expansion roadmap, with plans to strengthen its presence across Andhra Pradesh, Karnataka, Tamil Nadu, and Odisha before expanding across India by early 2027. It already holds a strong ground in Telangana. The company is also preparing for its entry into the US market by late 2027 or early 2028 as it continues to scale its AI-enabled healthcare solutions. As part of its innovation journey, DeepFacts has secured three granted patents, reinforcing the company's focus on building proprietary healthcare technologies. With a growing portfolio of intellectual property, expanding healthcare collaborations, and a clear roadmap for domestic and international growth, DeepFacts aims to accelerate the adoption of proRITHM, its AI-powered remote patient monitoring platform, while contributing to improved healthcare accessibility and outcomes. Vamsi Karatam, Founder & CEO of DeepFacts said "The future of healthcare lies in continuous, intelligent monitoring that enables timely interventions rather than reactive treatment. Our focus is to make clinically reliable remote monitoring accessible to healthcare providers across India while building globally relevant technology. The next phase of our expansion is centred on strengthening our presence in key Indian markets, deepening collaborations with healthcare partners, and preparing for international expansion."
CARPL.ai raises $10 M led by IFC to accelerate healthcare AI adoption globally
CARPL.ai, US and India-based radiology AI marketplace and enterprise platform, has announced a Series A round of $10 million led by International Finance Corporation (IFC), the private sector arm of the World Bank Group, with participation from Stellaris Venture Partners and other investors. The funding will accelerate CARPL’s mission to help healthcare providers adopt AI in a meaningful and safe manner. CARPL is being used by many governments, including Brazil, India, Singapore, Spain and the UAE. Through a single integration with CARPL, healthcare providers gain access to the world's largest radiology AI marketplace with more than 300 AI applications from over 100 partners. In addition to this, the CARPL platform also enables its customers to build, test, deploy, and monitor AI across clinical workflows while remaining vendor-neutral and infrastructure-agnostic. The investment will support continued product innovation, expansion of CARPL's global partner ecosystem, and commercial growth across North America, LATAM, Europe, Asia-Pacific, and emerging markets. The partnership also reflects a shared focus on advancing digital health innovation through CARPL’s model of building high-skill engineering, product development, and AI capabilities in India for deployment to healthcare providers around the world. While CARPL has started in the domain of radiology, which has 1000s of AI applications waiting to be deployed, the goal is to become the integration, utilisation and procurement layer for all clinical AI that goes into healthcare organisations. “We will soon move beyond medical imaging into the domains of pathology, genomics and general medicine, and one day, if there is a robotic surgeon somewhere using AI to perform surgery, we hope that it will be running through CARPL,” said Dr Vidur Mahajan, Chief Executive Officer of CARPL.ai.
ePlane Company inks MoU with Apollo Hospitals to deploy electric air ambulances and medical delivery drones
Chennai-based startup Ubifly Technologies (The ePlane Company) and Apollo Hospitals have signed a Memorandum of Understanding (MoU) to bring electric air ambulances and medical delivery drones into India's emergency healthcare system, connecting emergency patients across high-density urban corridors and remote access areas directly to the trauma care they need, without the delays of urban traffic or the expense of traditional helicopter transfers. For trauma, cardiac, and stroke patients, the first hour after an emergency often determines the difference between recovery and tragedy. Yet today, patients frequently lose that hour to traffic, distance, and the need to stabilise at any nearby facility before being moved again to specialised trauma care, thereby losing precious time. This collaboration is designed to change that with a faster, more direct path from the point of emergency to definitive care. ePlane's e200X aircraft is designed for rapid inter-hospital transfers, trauma response, cardiac and stroke emergencies, and organ transport, moving patients up to 7 times faster than road transport - at a fraction of the cost of a traditional helicopter transfer. Through its subsidiary Amber Wings, ePlane's unmanned aerial vehicles are designed to rapidly move blood products, organs, vaccines, medicines, and diagnostic samples between facilities - cutting critical delivery times from hours to minutes. As part of the collaboration, Apollo has indicated its intent to examine the possibility for orders for e200x air ambulances and Amber Wings' medical delivery drones. The MoU also outlines the possibility of a future strategic investment by Apollo in ePlane, subject to future agreement on terms. Both parties intend to work with India's Directorate General of Civil Aviation and other relevant authorities to help bring this vision to life, alongside continued discussions on infrastructure needed to support these operations.
#startup of the day 14 - MediElaj
Inception - 2023 Location - Faridabad, India Industry domain - Healthtech — AI-powered preventive healthcare, smart diagnostic kiosks, and health-tech app platform Founders - Debjit Patra, Founder & Chairman Total funds raised - Approximately $ 100,000 raised from friends and family, plus nearly USD 500,000 bootstrapped/invested by the founders into the tech platform, kiosk infrastructure, and operations roughly USD 600,000 in total capital deployed so far. Investors - Friends and family round (no named institutional or angel investors mentioned) Key Highlights - Official launch of the MediElaj AI-powered healthcare app and smart diagnostic kiosk platform Raised ~$100K in friends & family funding; ~$500K founder investment into product/tech Pilot kiosk deployed with 200+ patients served, with notable repeat usageBuilt out kiosk prototyping, healthcare device/sensor integration, cloud architecture, and software stack Founder Speaks - The company is focused on expanding its kiosk network across Tier 2 and Tier 3 cities, as well as rural and underserved districts, to improve access to preventive healthcare. To support this growth, it is strengthening its manufacturing capabilities for scalable kiosk production and establishing a nationwide deployment network to enable rapid installation and maintenance. Simultaneously, the company is advancing its AI-driven technology and cybersecurity infrastructure to ensure secure, intelligent, and reliable health monitoring. By forging strategic partnerships with private enterprises and public health institutions, it aims to accelerate adoption across diverse healthcare settings. Its long-term vision is to make routine, technology-enabled health monitoring universally accessible, enabling early detection and preventive care before health conditions escalate into serious crises. - Debjit Patra
#startup of the day 15 - IOTA Diagnostic Private Limited
Inception - June 2022 Location - Gandhinagar, Gujarat, India Industry domain - Health-Tech (Medical Devices & Diagnostics) — specializing in BioSampling and non-invasive self-sampling technologies for accessible healthcare Founders - Vaibhav Shitole — Founder & Managing Director, Prasoon Kumar — Co-founder, Pradeep Kumar Verma — Co-founder Team Strength - 15+ members (a multidisciplinary team of biologists, engineers, clinicians, and managers) Total funds raised - Rs 4 crore Investors - IIMA Ventures, DST-STBI Vadodara, and BizDateUp Technologies Revenue Generated - Over ₹80 Lakhs, achieved during the pilot launch and early commercial operations in Gujarat — demonstrating early market traction ahead of a wider rollout Key Highlights - Prix Galien India Award — Best Startup (2026), for M-Strip's path-breaking innovation in cervical cancer screening IIM-A Healthcare Summit (2025) — recognized by Union Health Minister Shri J.P. Nadda Winner, TiECon Vadodara (2025) and International Winner, PhilippineNext (2025), supported by DOST-TAPI, Philippines M-Strip™ — India's 1st CDSCO-approved, non-invasive HPV self-screening kit — reached 5,000+ women screened with 95%+ concordance to direct cervical smears; 96% of women preferred it over traditional methods Featured across 50+ national and regional media publications Founder Speaks - IOTA Diagnostic aims to scale M-Strip™ deployment across rural and underserved regions of India, working toward the WHO's 70% cervical cancer screening-coverage target. Plans include expanding the BioSampler® device platform into new diagnostic applications, securing international patents (currently filed), and entering global markets — making cervical cancer screening accessible and, in the long run, delivering patient-centric diagnostics to every corner of the world. - Vaibhav Shitole
Startups Spotlight
Ecosystem partners
BioStartups for you
Media Kit
Your guide to impactful promotions and strategic brand positioning.
BioStartups Spotlight
Showcase your startup, build your brand, and shine in biotech!
BioStartups Directory
Where Connections Fuel Biotech Innovations.
CEO & Founder Conclave 2024
BioStartups' flagship gathering of biotech leadership.
Biotech Innovations & Supplier Conclave 2024
Connecting suppliers with India's biotech manufacturers.
Founders & Investors Forum 2025
Synergy in biotech — connecting visionaries and venture capitalists.
